This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cyclacel Pharmaceuticals 将来の成長

Future 基準チェック /56

Cyclacel Pharmaceuticalsは、52.2%と57.5%でそれぞれ年率52.2%で利益と収益が成長すると予測される一方、EPSはgrowで46.4%年率。

主要情報

52.2%

収益成長率

46.4%

EPS成長率

Biotechs 収益成長	30.2%
収益成長率	57.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	17 Jan 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:UXI - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	56	25	N/A	N/A	1
12/31/2025	N/A	-27	N/A	N/A	1
12/31/2024	N/A	-24	N/A	N/A	2
12/31/2023	0	-23	N/A	N/A	3
9/30/2023	0	-25	-17	-17	N/A
6/30/2023	0	-24	-20	-20	N/A
3/31/2023	N/A	-23	-21	-21	N/A
12/31/2022	N/A	-21	-21	-21	N/A
9/30/2022	N/A	-19	-20	-20	N/A
6/30/2022	N/A	-19	-19	-19	N/A
3/31/2022	N/A	-20	-22	-22	N/A
12/31/2021	N/A	-19	-19	-19	N/A
9/30/2021	N/A	-20	-15	-15	N/A
6/30/2021	N/A	-18	-11	-11	N/A
3/31/2021	N/A	-15	-9	-9	N/A
12/31/2020	N/A	-12	-8	-8	N/A
9/30/2020	N/A	-8	-8	-8	N/A
6/30/2020	N/A	-8	-8	-8	N/A
3/31/2020	N/A	-7	-9	-9	N/A
12/31/2019	N/A	-8	-9	-9	N/A
9/30/2019	0	-8	-10	-10	N/A
6/30/2019	0	-8	-9	-9	N/A
3/31/2019	0	-8	-8	-8	N/A
12/31/2018	0	-7	-7	-7	N/A
9/30/2018	N/A	-8	-7	-7	N/A
6/30/2018	N/A	-14	-7	-7	N/A
3/31/2018	N/A	-15	-6	-6	N/A
12/31/2017	N/A	-15	-7	-7	N/A
9/30/2017	0	-16	-8	-8	N/A
6/30/2017	0	-10	N/A	-10	N/A
3/31/2017	1	-11	N/A	-11	N/A
12/31/2016	1	-12	N/A	-10	N/A
9/30/2016	1	-13	N/A	-10	N/A
6/30/2016	1	-12	N/A	-11	N/A
3/31/2016	2	-13	N/A	-13	N/A
12/31/2015	2	-15	N/A	-14	N/A
9/30/2015	2	-16	N/A	-15	N/A
6/30/2015	2	-18	N/A	-18	N/A
3/31/2015	2	-20	N/A	-19	N/A
12/31/2014	2	-20	N/A	-19	N/A
9/30/2014	2	-18	N/A	-20	N/A
6/30/2014	1	-19	N/A	-16	N/A
3/31/2014	1	-13	N/A	-18	N/A
12/31/2013	1	-20	N/A	-18	N/A
9/30/2013	1	-21	N/A	-15	N/A
6/30/2013	1	-18	N/A	-15	N/A
3/31/2013	0	-23	N/A	-14	N/A

アナリストによる今後の成長予測

収入対貯蓄率: UXIは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 0.6% ) よりも高い成長率であると考えられます。

収益対市場: UXI今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: UXI今後 3 年以内に収益を上げることが予想されます。

収益対市場: UXIの収益 ( 57.5% ) German市場 ( 5.1% ) よりも速いペースで成長すると予測されています。

高い収益成長: UXIの収益 ( 57.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: UXIの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

This company listing is no longer active

Cyclacel Pharmaceuticals 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Recent updates

Cyclacel Pharmaceuticals, Inc. Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as Precision Medicine for Cancer

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Cyclacel Pharmaceuticals, Inc. announced that it has received $8.000001 million in funding

Cyclacel Pharmaceuticals, Inc. has withdrawn its Follow-on Equity Offering in the amount of $30 million.

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq Related to Shareholder's Equity

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 19, 2024

Cyclacel Pharmaceuticals, Inc. Announces Board Changes

Cyclacel Pharmaceuticals, Inc. Announces Executive Changes

Cyclacel Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.525241 million.

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions

Cyclacel Pharmaceuticals Receives a Written Notice from the Nasdaq Stock Market

Cyclacel Pharmaceuticals, Inc. announced delayed 10-Q filing

New major risk - Revenue and earnings growth

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Cyclacel Pharmaceuticals, Inc. Reports Preliminary Data from its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients with Solid Tumors and Lymphoma at ENA 2022

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Cyclacel Pharmaceuticals, Inc. Appoints Kenneth M. Ferguson as a Class 1 Director

Cyclacel Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Cyc140 in Patients with Advanced Solid Tumors and Lymphomas

Cyclacel Pharmaceuticals Announces Publication Confirming Fadraciclib Suppresses MCL1 and Synergizes With Venetoclax in Chronic Lymphocytic Leukemia

Cyclacel Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients with Advanced Solid Tumors and Aggressive Lymphomas

Cyclacel Pharmaceuticals Announces Management Changes

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Cyclacel Pharmaceuticals Announces the Election of Brian Schwartz, M.D. to Its Board of Directors

Cyclacel Pharmaceuticals, Inc. Appoints Karin L. Walker as Class 1 Director

Cyclacel Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 11, 2020

Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients with Advanced Solid Tumors At the EORTC-NCI-AACR Symposium 2020

Cyclacel Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 12, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘